Connect Biopharma Holdings Limited Ordinary Shares

CNTBNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
2.15 USD
↘ 0.19 (8.12%)AT CLOSE (11:59 AM EDT)
2.33
↗ 0.18 (8.19%)
POST MARKET (AS OF 05:15 PM EDT)
Post Market
AS OF 05:15 PM EDT
2.33
↗ 0.18 (8.19%)
🟢Market: OPEN
Open?$2.34
High?$2.36
Low?$2.15
Prev. Close?$2.34
Volume?223.8K
Avg. Volume?183.6K
VWAP?$2.22
Rel. Volume?1.22x
Bid / Ask
Bid?$1.86 × 100
Ask?$2.76 × 100
Spread?$0.90
Midpoint?$2.31
Valuation & Ratios
Market Cap?147.3M
Shares Out?63.0M
Float?12.0M
Float %?21.5%
P/E Ratio?N/A
P/B Ratio?3.46
EPS?-$1.03
Dividend?0.00%
Ex-Dividend?N/A

Shares of Connect Biopharma Holdings Limited Ordinary Shares (CNTB) are trading at $2.33. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation front, CNTB trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Jun 2, 2026.

News
Profile
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Themes
Biotech - Drug Development›Immunology & Autoimmune
Employees
64
Market Cap
147.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.connectbiopharm.com
Listed
2025-09-03
Address
3580 CARMEL MOUNTAIN ROAD, SUITE 200
SAN DIEGO, CA 92130
Phone: 858-727-1040
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
23
Short Sent.?
34
Piotroski F-Score?0/9Weak
Altman Z-Score?-7.60Distress
Confidence?57%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?9.62%Elevated
Short Interest?1.2M
Days to Cover?8.3
Free Float12.0M
Avg Daily Volume140.3K
Settlement Date2026-05-15
Financial Health
Current Ratio?3.23Strong
Quick Ratio?3.23Strong
Cash Ratio?2.70Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
49
3.46FAIR▾
P/S?
Peers
100
S&P
3
632.34HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.5CHEAP▾
EV/Sales?
Peers
100
S&P
3
434.77HIGH▾
Returns & Efficiency
ROE?
S&P
3
-152.3%WEAK▾
ROA?
S&P
3
-108.0%WEAK▾
Cash Flow & Enterprise
FCF?$-57605000
Enterprise Value?$101.3M
Fundamentals ratios updated end of day
MarketsMoversWatchlist